Abstract
Breast cancer is the leading incident cancer and the second highest cause of cancer mortality in the U.S. In 2004, breast cancer treatment expenditures were $8.1 billion [1], and may account for as much as 1% of healthcare expenditures in the U.S. [2]. Increased early detection has led to a shift towards diagnosis of early stage cancer and with the array of adjuvant therapies available, average survival has improved over time [3]. Primary therapy for early breast cancer is commonly surgery. Following surgery, chemotherapy and endocrine therapy are used alone or in combination to kill cancer cells that have spread throughout the body, because a high percentage of patients with localized disease have undetectable metastases [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
National Cancer Institute. Cancer trends progress report – 2005 update.
Radice D, Redaelli A. Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics. 2003;21(6):383–96.
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, et al. SEER Cancer Statistics Review, 1975–2003 Bethesda, MD: National Cancer Institute, 2006.
Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet. 1998;352(9132):930–42.
Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93(13):979–89.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351(9114):1451–67.
Carlson R, Anderson B, Burstein H, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer: National Comprehensive Cancer Network, 2007.
Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst. 2002;94(21):1626–34.
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.
Habel L, Quesenberry C, Jacobs M, Greenberg D, Fehrenbacher L, Alexander C, et al. Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study American Society for Clinical Oncology Annual Meeting. 2005.
Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7(6):380–9.
Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11(5):313–24.
Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101(6):1311–22.
Gold ME, Russell LB, Siegel JE, Weinstein ME. Cost-effectiveness in Health and Medicine New York: Oxford University Press, 1996.
Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 2005;104(10):2054–62.
Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. J Natl Cancer Inst Monogr. 1992(11):143–9.
Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87(6):417–26.
Garrison L, Perez E, Dueck A, Lalla D, Paton V, Lubeck D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer. J Clin Oncol. 2006;24(18S):6023.
Fireman BH, Quesenberry CP, Somkin CP, Jacobson AS, Baer D, West D, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18(4):51–76.
Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care. 1991;29(1):40–9.
Lober J, Sogaard J, Mouridsen HT, Jorgensen J. Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients. Acta Oncol. 1988;27(6A):767–71.
Irvin R, Kuhn J. Financial considerations in the use of adjuvant chemotherapy. In: Henderson I, ed. Adjuvant Therapy of Breast Cancer. Boston: Kluwer Academic Publishers, 1992.
Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health. 1980;70(12):1249–60.
Johnston K, Gerard K, Brown J. Generalizing costs from trials. Analyzing center selection bias in a breast screening trial. Int J Technol Assess Health Care. 1998;14(3):494–504.
Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138(2):90–7.
Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol. 2005;23(36):9079–88.
Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: Economic cost and quality of life. Annu Rev Public Health. 2001;22:91–113.
Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002;20(1):307–16.
Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M. Cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst. 2001;93(6):447–55.
Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA. 1995;273(2):142–8.
Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33(8):828–41.
van Enckevort PJ, TenVergert EM, Schrantee S, Rutten FF, de Vries EG. Economic evaluations of systemic adjuvant breast cancer treatments: Methodological issues and a critical review. Crit Rev Oncol Hematol. 1999;32(2):113–24.
Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med. 1991;324(3):160–8.
Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat. 1993;25(2):97–105.
Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol. 1993;11(4):771–6.
Friedlander ML, Tattersall MH. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol. 1982;18(12):1237–41.
Wolstenholme JL, Smith SJ, Whynes DK. The costs of treating breast cancer in the United Kingdom: Implications for screening. Int J Technol Assess Health Care. 1998;14(2):277–89.
Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer. 1994;30A(1):60–5.
Kruijshaar ME, Barendregt JJ. The breast cancer related burden of morbidity and mortality in six European countries: the European Disability Weights project. Eur J Public Health. 2004;14(2):141–6.
Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer. 2004;91(1):77–83.
Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36(6):724–35.
McArdle CS, Calman KC, Cooper AF, Hughson AV, Russell AR, Smith DC. The social, emotional and financial implications of adjuvant chemotherapy in breast cancer. Br J Surg. 1981;68(4):261–4.
Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer: Practice patterns of community physicians. J Clin Oncol. 2002;20(7):1809–17.
Naeim A, Keeler EB. Is adjuvant therapy for older patients with node (+) early breast cancercost-effective?*. Breast Cancer Res Treat. 2005;94(2):95–103.
Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005;6(11):886–98.
Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer – is it cost-effective? Acta Oncol. 2000;39(1):33–9.
Butler JR, Furnival CM, Hart RF. The costs of treating breast cancer in Australia and the implications for breast cancer screening. Aust N Z J Surg. 1995;65(7):485–91.
Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol. 1996;51(2):111–6.
Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration – Part two. Use of charges versus reimbursement for cost basis. Cancer. 1996;78(2):300–3.
Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21(1):28–34.
Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer. 2002;38(15):1984–6.
Winer E, Hudis C, Burstein H, et al. Use of aromatase inhibitors as adjuvant therapy for postmenopaual women with hormone receptor-positive breast cancer: Status report 2004: ASCO. 2006.
Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat. 2007;101(1):37–49.
Lonning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006;17(2):217–25.
Calabro A, Garcia M, Portella M. A budget impact analysis of extended adjuvant letrozole following 5 years of tamoxifen in postmenopausal women with early breast cancer American Society of Clinical Oncology Annual Meeting. 2006.
Longman AJ, Braden CJ, Mishel MH. Side effects burden in women with breast cancer. Cancer Pract. 1996;4(5):274–80.
De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther. 2005;27(8):1295–310.
Ozer H, Armitage J, Bennett C, et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol. 2000;18:3558–85.
Hillner B, Ingle J, Chlebowski R, et al. 2003 ASCO update on the role of bisphosphonates and bone health issues in women with breast cancer, 2006.
GlaxoSmithKline. Tykerb® website. www.tykerb.com. Accessed April 1, 2007.
Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care. 2005;21(1):132–7.
Drucker A, Virik K, Skedgel C, Payson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it? J Clin Oncol. 2006;24(18S):6044.
Tollestrup K, Frost FJ, Stidley CA, Bedrick E, McMillan G, Kunde T, et al. The excess costs of breast cancer health care in Hispanic and non-Hispanic female members of a managed care organization. Breast Cancer Res Treat. 2001;66(1):25–31.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373–83.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
Given BA, Given CW, Stommel M. Family and out-of-pocket costs for women with breast cancer. Cancer Pract. 1994;2(3):187–93.
Grunfeld E, Coyle D, Whelan T, Clinch J, Reyno L, Earle CC, et al. Family caregiver burden: Results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ. 2004;170(12):1795–801.
Lauzier S, Maunsell E, De Koninck M, Drolet M, Hebert-Croteau N, Robert J. Conceptualization and sources of costs from breast cancer: findings from patient and caregiver focus groups. Psychooncology. 2005;14(5):351–60.
Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 2006;24(3):345–53.
Drolet M, Maunsell E, Mondor M, Brisson C, Brisson J, Masse B, et al. Work absence after breast cancer diagnosis: a population-based study. CMAJ. 2005;173(7):765–71.
Chirikos TN, Russell-Jacobs A, Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract. 2002;10(5):248–55.
Moore KA. Breast cancer patients' out-of-pocket expenses. Cancer Nurs. 1999;22(5):389–96.
Arozullah AM, Calhoun EA, Wolf M, Finley DK, Fitzner KA, Heckinger EA, et al. The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol. 2004;2(3):271–8.
Secker-Walker RH, Vacek PM, Hooper GJ, Plante DA, Detsky AS. Screening for breast cancer: time, travel, and out-of-pocket expenses. J Natl Cancer Inst. 1999;91(8):702–8.
Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55–61.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Oestreicher, N. (2009). Costs of Adjuvant Breast Cancer Treatments. In: Castiglione, M., Piccart, M. (eds) Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-75115-3_25
Download citation
DOI: https://doi.org/10.1007/978-0-387-75115-3_25
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-75114-6
Online ISBN: 978-0-387-75115-3
eBook Packages: MedicineMedicine (R0)